ProMed Pharma adds second manufacturing suite at Plymouth site

ProMed Pharma has signed a second dedicated-suite agreement at its Niagara Lane facility in Plymouth, Minnesota, expanding capacity for highly potent APIs and complex generic drug products. The move signals stronger demand for specialized manufacturing space tied to long-acting and sustained-release therapies.

Why it matters: - The new suite expands ProMed Pharma’s capacity for highly potent active pharmaceutical ingredients and complex generic drug products. - The agreement underscores demand for dedicated manufacturing space for long-acting and sustained-release therapies. - The Niagara Lane buildout gives pharmaceutical partners access to specialized production space without building their own facilities.

What happened: - ProMed Pharma announced a second dedicated manufacturing suite agreement at its Niagara Lane facility in Plymouth, Minnesota. - The company entered the agreement with an undisclosed pharmaceutical partner. - The suite is designed for HPAPI handling and future commercial production of complex generic drug products. - The announcement came June 23, 2026.

The details: - The new suite will use advanced containment technologies, material flows and environmental controls. - The suite is intended to meet current Good Manufacturing Practice requirements. - ProMed will use its hot melt extrusion and polymer-based drug delivery expertise to support development and commercialization. - The Niagara Lane facility already has one other dedicated suite commitment in its expansion plan. - The site was designed with shared GMP infrastructure, quality systems, warehousing and material management. - ProMed says the facility retains additional capacity for future pharmaceutical and biotechnology partners. - ProMed Pharma focuses on drug-releasing implants and combination products. - The company also specializes in hot melt extrusion and injection molding of drug-loaded polymers. - ProMed supports controlled-release formulations for ophthalmic, implantable and combination-product applications.

Between the lines: - The second suite commitment suggests the company’s dedicated-suite model is gaining traction. - The HPAPI capability broadens the types of programs ProMed can support. - The move also positions ProMed more directly in the complex generic market, where manufacturers look for specialized technical and containment capabilities.

What's next: - The Niagara Lane facility will move toward supporting development work and eventual commercial production under the new agreement. - ProMed is still marketing remaining capacity to future pharmaceutical and biotechnology partners. - The company is likely to continue pitching its purpose-built model to developers that need specialized manufacturing without major capital investment.

The bottom line: - ProMed Pharma is turning its Plymouth site into a larger specialized manufacturing hub, with a second suite now committed and room for more partnerships.